Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) EVP Tao Fu sold 5,812 shares of the firm’s stock in a transaction on Tuesday, July 18th. The shares were sold at an average price of $65.00, for a total value of $377,780.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.
Tao Fu also recently made the following trade(s):
- On Monday, June 26th, Tao Fu sold 7,000 shares of Portola Pharmaceuticals stock. The shares were sold at an average price of $57.14, for a total value of $399,980.00.
Shares of Portola Pharmaceuticals, Inc. (PTLA) traded up 0.48% on Thursday, hitting $65.29. The stock had a trading volume of 864,841 shares. The firm has a 50 day moving average price of $48.58 and a 200-day moving average price of $38.17. Portola Pharmaceuticals, Inc. has a 52 week low of $15.68 and a 52 week high of $67.10. The company’s market cap is $3.72 billion.
Portola Pharmaceuticals (NASDAQ:PTLA) last posted its quarterly earnings data on Monday, May 8th. The biopharmaceutical company reported ($0.74) EPS for the quarter, topping analysts’ consensus estimates of ($1.20) by $0.46. The company had revenue of $5.12 million for the quarter, compared to analyst estimates of $4.21 million. Portola Pharmaceuticals had a negative return on equity of 106.68% and a negative net margin of 759.21%. The business’s revenue was down 37.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($1.15) earnings per share. Analysts anticipate that Portola Pharmaceuticals, Inc. will post ($4.30) EPS for the current year.
COPYRIGHT VIOLATION NOTICE: “Portola Pharmaceuticals, Inc. (PTLA) EVP Tao Fu Sells 5,812 Shares” was first reported by BNB Daily and is the property of of BNB Daily. If you are accessing this piece of content on another domain, it was stolen and republished in violation of international copyright & trademark legislation. The original version of this piece of content can be accessed at https://www.baseball-news-blog.com/2017/07/20/portola-pharmaceuticals-inc-ptla-evp-tao-fu-sells-5812-shares.html.
A number of equities research analysts have issued reports on PTLA shares. Oppenheimer Holdings, Inc. set a $46.00 target price on Portola Pharmaceuticals and gave the company a “buy” rating in a research note on Tuesday, May 9th. Citigroup Inc. set a $51.00 target price on Portola Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, April 19th. Credit Suisse Group reissued a “neutral” rating and set a $58.00 price target (up from $39.00) on shares of Portola Pharmaceuticals in a report on Monday, June 26th. Morgan Stanley raised their price target on Portola Pharmaceuticals from $50.00 to $70.00 and gave the company an “overweight” rating in a report on Monday, June 26th. Finally, ValuEngine raised Portola Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, June 2nd. Four investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $60.52.
A number of institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. boosted its position in shares of Portola Pharmaceuticals by 4.4% in the first quarter. Vanguard Group Inc. now owns 4,614,814 shares of the biopharmaceutical company’s stock worth $180,855,000 after buying an additional 192,420 shares during the period. BlackRock Inc. boosted its position in shares of Portola Pharmaceuticals by 68,964.1% in the first quarter. BlackRock Inc. now owns 4,034,725 shares of the biopharmaceutical company’s stock worth $158,121,000 after buying an additional 4,028,883 shares during the period. FMR LLC boosted its position in shares of Portola Pharmaceuticals by 5.6% in the first quarter. FMR LLC now owns 3,902,000 shares of the biopharmaceutical company’s stock worth $152,919,000 after buying an additional 205,751 shares during the period. Geode Capital Management LLC boosted its position in shares of Portola Pharmaceuticals by 9.4% in the first quarter. Geode Capital Management LLC now owns 481,732 shares of the biopharmaceutical company’s stock worth $18,879,000 after buying an additional 41,524 shares during the period. Finally, Norges Bank acquired a new position in shares of Portola Pharmaceuticals during the fourth quarter worth $10,046,000. 85.23% of the stock is currently owned by institutional investors.
Portola Pharmaceuticals Company Profile
Portola Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients having limited or no approved treatment options. The Company’s two lead programs, Betrixaban and Andexanet alfa, address unmet medical needs in the area of thrombosis, or blood clots.